The FDA asks the court to stop producing Pfizer BLA documentation. Motion for summary judgement filed 10/17/2024. By Sasha Latypova (10/23/24)
On 09/16/21 Aaron Siri file a lawsuit that ultimately forced the FDA to produce ~55K pages of Pfizer BLA documentation per month. The suit was filed on behalf of the Public Health and Medical Professionals for Transparency (PHMPT), a group of medical and public health professionals and scientists from Harvard, Yale, UCLA and other institutions.
The suit asked for “all data and information for the Pfizer Vaccine,” including safety and effectiveness data, adverse reaction reports, and a list of active and inactive ingredients.
The FDA produced these pages every month for about a year and a half, but the productions ended in November 2023. On October 17, 2024, the FDA filed a motion for summary judgement asking the court to declare the case closed.
The FDA is now saying “we have produced 1.2 million pages of Pfizer documentation that was used to license Pfizer’s Comirnaty, and this constitutes everything we were mandated to do by the court.”
Latypova explains in depth why this case against the FDA should not be closed. Bottom line: the required production simply is NOT complete, especially with respect to manufacturing processes.
She stated that the documents released so far by the FDA are “inadequate” to assess the quality of Pfizer’s COVID-19 vaccine manufacturing process; there should have been thousands of pages of manufacturing documents, yet almost none have been produced.
She further states (after presenting extensive evidence, including leaked evidence) that the FDA was providing these communications to the EU regulators on a regular basis, and that the FDA also has these documents.
In conclusion, this shows that the FDA has in their possession numerous materials revealing their own knowledge that Comirnaty “as dispensed” is a poison (legally indistinguishable from poison due to no cGMP** compliance and known presence of toxic materials), and that they lied not only to the US public about it, but to other global regulators (EMA and Canada). Albeit, I do believe the senior management at both EMA and Canada were complicit.
Therefore, it is crucial in my opinion to continue this lawsuit and demand that the FDA produces the missing manufacturing process documentation among other materials that have not been produced yet.
As usual, Latypova’s substack article contains links to and screen shots of source materials.
** Definition: cGMP (Per Wikipedia) **
Current good manufacturing practices (cGMP) are those conforming to the guidelines recommended by relevant agencies. Those agencies control the authorization and licensing of the manufacture and sale of … pharmaceutical products … and medical devices. These guidelines provide minimum requirements that a manufacturer must meet to assure that their products are consistently high in quality, from batch to batch, for their intended use.
